Jubilant Pharmova Ltd.
Snapshot View

686.10 +1.05 ▲0.2%

30 July 2021, 04:00:00 P.M.
Volume: 39,720

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.jubl.com
Financial Indicators
Market Cap 10,942.61 Cr.
Earnings per share (EPS) 57.03 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 12.05 Trailing Twelve Months Ending 2021-06
Industry PE 35.15 Trailing Twelve Months Ending 2021-06
Book Value / Share 308.38 Trailing Twelve Months Ending 2021-06
Price to Book Value 2.23 Calculated using Price: 687.00
Dividend Yield 0.73 Period Ending 2020-03
No. of Shares Subscribed 15.93 Cr. 159,281,139 Shares
FaceValue 1
Company Profile

Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.

The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.

The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.

Business area of the company

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Business segments

  • Pharmaceuticals
  • Life Science Ingredients
  • Drug Discovery & Development Solutions
  • India Branded Pharmaceuticals

Awards

2012

  • NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
  • Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.

2013

  • Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
  • Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
  • Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.

2014

  • Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
  • BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
  • Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
  • IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
  • Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
  • Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.

2015

  • Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
  • Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.

2016

  • Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
  • Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
  • 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.

2017

  • Social Entrepreneur of the Year (SEOY)-India Award 2017.
  • Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
  • ‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.15%
1 Week
-1.55%
1 Month
-6.24%
3 Month
-14.02%
6 Month
-22.61%
1 Year
-11.97%
2 Year
+54.41%
5 Year
+104.71%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 2.06 7.98 5.39 -1.58 14.27 17.95 16.87 12.97 17.25
Return on Capital Employed (%) 5.79 10.19 7.92 5.72 12.42 14.44 15.21 13.06 15.07
Return on Assets (%) 0.60 2.34 1.60 -0.46 4.46 6.52 6.91 5.55 7.60

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2,257 2,476 2,627 2,454 2,966 3,436 4,087 4,809 5,604
Non Curr. Liab. 3,224 3,005 2,185 4,036 3,347 3,826 3,417 4,420 4,088
Curr. Liab. 2,213 2,778 3,894 2,129 2,464 1,684 2,005 2,090 2,619
Minority Int. 69 112 158 -38 -47 -52 0
Equity & Liab. 7,763 8,371 8,864 8,619 8,740 8,899 9,457 11,319 12,310
Non Curr. Assets 5,466 5,810 5,936 5,904 5,864 5,951 6,267 6,734 7,272
Curr. Assets 2,297 2,561 2,928 2,715 2,875 2,948 3,190 4,585 5,038
Misc. Exp. not W/O
Total Assets 7,763 8,371 8,864 8,619 8,740 8,899 9,457 11,319 12,310

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 4,303 5,166 5,803 5,826 5,749 5,861 7,518 9,111 9,154
Other Income 31 30 19 42 13 25 40 36 47
Total Income 4,335 5,196 5,822 5,869 5,763 5,886 7,558 9,147 9,202
Total Expenditure -3,413 -4,098 -4,782 -5,125 -4,502 -4,516 -5,999 -7,372 -7,207
PBIDT 922 1,098 1,040 744 1,260 1,370 1,558 1,775 1,995
Interest -238 -311 -337 -368 -371 -341 -284 -220 -287
Depreciation -221 -254 -281 -288 -347 -291 -415 -371 -462
Taxation -68 -152 -70 -80 -155 -163 -225 -327 -312
Exceptional Items -349 -192 -214 -48 -280 -35
PAT 46 189 138 -40 387 575 634 577 898

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 707 970 772 783 1,099 1,268 1,303 1,122 1,543
Cash Fr. Inv. -594 -500 -174 -343 -313 -450 -618 -1,012 -327
Cash Fr. Finan. -889 -450 -414 -503 -843 -686 -901 657 -1,050
Net Change -776 20 183 -63 -56 132 -216 767 166
Cash & Cash Eqvt 263 280 473 392 339 456 244 1,005 1,231

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 50.68 50.68 50.68 50.68 50.68 50.68 50.68 50.68 50.68
Public 49.32 49.32 49.32 49.32 49.32 49.32 49.32 49.32 49.32
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 27 Jul 2021
Intimation Of Record Date For The Purpose Of Declaration Of Dividend For The Financial Year 2020-21
We refer to our letter dated June 4 2021 intimating recommendation by the Board of Directors for a dividend of Rs. 5 (Rupees Five only) per equity share of Re. 1 each for the year ended March 31 2021. The dividend is subject to approval of the shareholders at the ensuing Annual General Meeting (AGM).

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Company has fixed Friday August 6 2021 as the Record Date for the purpose of determining names of the Members eligible for the dividend. The dividend if approved by the shareholders at the ensuing AGM will be paid/ dispatched on or before October 20 2021.
Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of Jubilant Pharmova Limited (JPM) at its meeting held on July 23 2021 has approved the demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited (JGL - a wholly owned subsidiary of the Company) and vesting of the same with JPM on a going concern basis (Proposed Demerger) to be implemented through a scheme of arrangement between JGL and JPM and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act 2013 (Proposed Scheme).

The details as required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular dated September 9 2015 are enclosed at Annexure A.

Kindly take the above information on record.
Fri, 23 Jul 2021
Results For Quarter Ended June 30 2021
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30 2021 were approved by the Board of Directors of the Company at its meeting held today at 1:30 p.m. and concluded at 4.00 p.m.

Pursuant to the applicable provisions of the Listing Regulations we enclose the following:

1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30 2021;

2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and

3. Copies of the Press Release and Presentation.

We request you to take the same on records.

Technical Scans View Details

Fri, 30 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Both SRS And ARS Below Zero Both SRS And ARS Below Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%